Oxyrane UK Ltd has raised $26.5 million in a Series D financing to support the development of its enzyme replacement therapies for lysosomal storage diseases. The round was led by Morningside and joined by Forbion Capital Partners. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
